Shasun Chemicals and Drugs Ltd; announced that it's wholly-owned UK-subsidiary Shasun Pharma Solutions Ltd has entered into non-exclusive licensing agreement with H Lundbeck, a research based Danish company engaged in finding new drugs for treatment of CNS (Central Nervous System) disorders.

Under the terms of the agreement, Shasun Pharma grants H Lundbeck the use of its proprietary cross-coupling technology (also known as Buchwald technology) to manufacture and commercialise new APIs (Active Pharmaceutical Ingredients). The Buchwald cross-coupling technology is one of the most referred to technologies in the pharmaceutical area allowing increasing complex new drugs to be manufactured in a more straightforward and economical way.

Commenting on the development, Dr Michel Spagnol, vice president, Lundbeck said, "Lundbeck will have access to one of the most powerful cross-coupling technologies allowing them to speed up the development of new drugs while reducing the cost of manufacture."

Govindarajan, CEO and MD of Shasun Chemicals and Drugs added, "This is yet another example of Shasun's flexibility in dealing with the management of its Intellectual Property and making sure that it services its customer first!"